CAPR - What's Going On With Capricor Therapeutics Stock Tuesday? | Benzinga
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is trading higher Tuesday after the company announced three-year results from the ongoing HOPE-2 open-label extension study with CAP-1002.
HOPE-2, a Phase 2 clinical study, assessed Capricor’s CAP-1002 therapy in boys and young men with DMD. According to results, patients treated with CAP-1002 continued to show benefits ...